This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Antibody Engineering & Therapeutics US
December 15 - 18, 2024
Marriott Marquis San DiegoLive In-Person Event: December 15 - 18, 2024

Mark Yarmarkovich, PhD
Assistant Professor, Department of Pathology at NYU Langone Health


Dr. Mark Yarmarkovich is an Assistant Professor at NYU Grossman School of Medicine focused on developing safe and effective cancer immunotherapies through innovations in biotechnology. He has worked in industry at Genentech and completed his PhD at the University of Pennsylvania and postdoctoral work at the Children's Hospital of Philadelphia, working across a number of disciplines including oncology, protein chemistry, immunology, and computational biology. He applies these experiences to addressing the major challenges in developing the next generation of immunotherapies, leading the development of new technologies for the discovery of tumor-specific targets and the engineering of target-specific receptors. He has discovered novel immunotherapy targets derived from previously undruggable oncoproteins and engineered CAR T cells capable of specifically killing tumor cells. He led the discovery of cross-HLA recognition of Peptide-Centric (PC)-CAR T cells, allowing for significantly expanded application of immunotherapies. Collectively, the application of his efforts has resulted in a PC-CAR T cells entering first-in-class clinical trial in pediatric neuroblastoma in 2024 and a pipeline of PC-CARs being additional cancers. His lab is focused on developing the next generation of immunotherapies to help cancer patients in need.

Agenda Sessions

  • Targeting Intracellular Cancer Drivers using Peptide Centric (PC)-CAR T Cells